FDA CDER Drug Supply Chain (DSC)

FDA CDER Drug Supply Chain (DSC)

Food and Drug Administration (FDA) [HHS]

On March 27, 2020, the President signed the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which amended the FD&C Act to require drug manufacturers registered under Section 510. The Drug Supply Chain investment is FDA's response to the CARES Act which provides surveillance and insight into the whole end-to-end drug supply chain from raw materials to clinical settings such as hospitals and pharmacies. The purpose of the Drug Supply Chain (COVID-19) (DSC) project is to facilitate a coordinated approach and infrastructure to support data collection and analysis activities. The purpose of the Drug Supply Identify & Trace, Drug Shortage Modernization (DSIT) project is to establish systems that will collect and analyze drug manufacturer and distributor data in order to address supply chain vulnerabilities, including IT-related activities, and safeguard the supply of medical products in the United States.

Major IT Investments

0